The results revealed that high expression of ADORA1 (HR=2.87, 95% CI: 1.25-6.6, and p=0.0094) was associated with a worse disease free survival in the thyroid carcinoma patients while high expression of ADORA1 (HR=0.36, 95% CI: 0.14-0.97, and p=0.035) was associated with a longer overall survival (Figure 3). This evidence concerns the gene ADORA1 and thyroid gland carcinoma.